MeiraGTx Holdings plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
MeiraGTx Holdings plc (MGTX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $22.14 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-13
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $22.14M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $5.25M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $4.04K.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $4.65K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value |
|---|---|
| 2026-06-30 | $22.14M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $5.25M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $4.04K 10-K · filed 2026-03-30 |
| 2025-09-30 | $4.65K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $2.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $2.23K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $1.42K 10-K · filed 2025-03-13 |
| 2024-09-30 | $526.00 10-Q · filed 2024-11-13 |
| 2024-06-30 | $540.00 10-Q · filed 2024-08-12 |
| 2024-03-31 | $1.41K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $2.26K 10-K · filed 2024-03-15 |
| 2023-09-30 | $790.00 10-Q · filed 2023-11-14 |
| 2023-06-30 | $2.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $882.00 10-Q · filed 2023-05-11 |
| 2022-12-31 | $1.82K 10-K · filed 2023-03-14 |
| 2022-09-30 | $3.83K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $2.80K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $15.69K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $62.70K 10-K · filed 2022-03-10 |
| 2021-09-30 | $14.91K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $22.70K 10-Q · filed 2021-08-11 |
| 2021-03-31 | $19.65K 10-Q · filed 2021-05-11 |
| 2020-12-31 | $22.34M 10-K · filed 2021-03-11 |
| 2020-09-30 | $16.47M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $14.62M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $17.47M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $39.26M 10-K · filed 2020-03-11 |
| 2019-03-31 | $32.00M 10-Q · filed 2019-05-14 |
| 2018-12-31 | $6.90M 10-Q · filed 2019-11-07 |
| 2018-09-30 | $13.34M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $9.88M 10-Q · filed 2018-08-08 |
| 2017-12-31 | $1.42M 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |